Get started
Author

Marı́a Jesús Moro

Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
1999 · R. Garcı́a-Sanz, A. Orfão, et al. · Blood · 333
PDF
Prognostic Value of Numerical Chromosome Aberrations in Multiple Myeloma: A FISH Analysis of 15 Different Chromosomes
1998 · J.A. Pérez-Simón, R. Garcı́a-Sanz, et al. · Blood · 169
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
2002 · Jesús F. San Miguel, Julia Almeida, et al. · Blood · 160
Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment
2005 · M Pérez-Andrés, J Almeida, et al. · Leukemia · 96
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
1996 · J Bladé, J F San Miguel, et al. · Journal of Clinical Oncology · 88
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival
2002 · Maria V. Mateos, Ramón García‐Sanz, et al. · British Journal of Haematology · 79
Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR‐Vβ repertoire
2006 · Martin Pérez‐Andres, Julia Almeida, et al. · Cancer · 65
PDF
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
1993 · J Bladé, J F San Miguel, et al. · Journal of Clinical Oncology · 59
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients
2001 · Joan Bladé, Jesús F San Miguel, et al. · The Hematology Journal · 57
Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study
2009 · GIUMO Study Group, Manuel Sosa, et al. · Aging Clinical and Experimental Research · 49
A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.
2004 · M.V. Mateos, Joan Blade, et al. · Blood · 39
Treatment of Multiple Myeloma in Elderly People: Long-term Results in 178 Patients
1996 · JOAN BLADÉ, MONTSERRAT MUÑOZ, et al. · Age and Ageing · 32
PDF
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
2001 · Maria Victoria Mateos, Ramón Garcia-Sanz, et al. · The Hematology Journal · 31
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease
2008 · Martin Perez‐Andres, Julia Almeida, et al. · International Journal of Cancer · 27
PDF
Combination of interferon and dexamethasone in refractory multiple myeloma
1990 · J. F. San Miguel, M. Moro, et al. · Hematological Oncology · 21
Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease
2011 · Manuel Sosa, Pedro Saavedra, et al. · Aging Clinical and Experimental Research · 18
PDF
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma
1990 · J. Bladé, J. San Miguel, et al. · Annals of Hematology · 15
A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.
2005 · M.V. Mateos, M. Hernández, et al. · Blood · 14
[Prognostic effect of beta 2-microglobulin in multiple myeloma].
1992 · F Ortega, M González, et al. · PubMed · 6
Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenstrom’s Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.
2005 · Norma C. Gutierrez, Enrique M. Ocio, et al. · Blood · 5
Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy
1991 · Jesús F. San Miguel, Maria Moro, et al. · European Journal of Cancer and Clinical Oncology · 4
6q Deletion in Waldenstrom Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.
2005 · Roelandt F.J. Schop, Enrique M. Ocio, et al. · Blood · 1
Clonality assessment in suspected cytotoxic T cell lymphoproliferations: To KIR or not to KIR
2019 · C. Quirós, A. Fonseca, et al. · Clinica Chimica Acta
P089 Ferritine, transferrine and IST as a bone marrow iron depot predictor
2007 · M. Barbón, E. de Cabo, et al. · Blood Reviews
Symptomatic and Indolent Waldenstrom’s Macroglobulinemia Display Different Biological and Cytogenetic but Not Immunophenotypic Characteristics.
2004 · Enrique M. Ocio, Gema Mateo, et al. · Blood
Works count: 27
Citation count: 1,368
H-index: 16
I10-index: 18
Year
Topic
Type